Physician

Albert S Hartel, MD

According to 2025 Medicare claims, Albert Hartel, MD (NPI: 1841304805) practices allergy/immunology in the Rochester, NY market, with the plurality of this provider's patient population coming from Monroe, NY. This provider's primary affiliated billing organization is ALLERGY ASTHMA IMMUNOLOGY OF ROCHESTER, PC (NPI: 1043288293; TIN: 161251533) and primary practice location at 14623-2928.

Hartel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 171 traditional Medicare patients, billed 34,314 HCPCS/CPT codes, and received $844,716 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,553 prescription claims across 510 beneficiaries totaling $921,706 in drug costs, led by Fasenra (Benralizumab). DME data shows 33 claims. Open Payments data shows 25 records totaling $404. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $10,937 to $844,716. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $942,452 and ending at $921,706. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	37	1,080	$10,937
2016	36	1,139	$10,944
2017	38	1,400	$14,613
2018	45	2,074	$20,688
2019	51	3,142	$34,798
2020	120	7,471	$280,606
2021	167	28,123	$1,191,523
2022	176	33,445	$1,027,196
2023	155	32,124	$878,730
2024	171	34,314	$844,716

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	104	598	$942,452
2016	123	684	$948,773
2017	138	744	$915,820
2018	159	796	$1,079,235
2019	183	959	$1,200,239
2020	265	1,142	$1,230,479
2021	307	1,454	$1,477,525
2022	264	1,344	$1,265,186
2023	267	1,255	$455,087
2024	510	2,553	$921,706

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$30
2021	N/R	14	$48,180
2022	N/R	11	$39,185
2023	N/R	23	$44,406
2024	N/R	33	$1,566

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	39	48	$91
94010	Test to measure expiratory airflow and volume	36	41	$19
95012	Test to measure the level of nitric oxide gas	34	39	$14
95165	Professional service for preparation and provision of 1 or more antigens	78	2,262	$10
95117	Professional service for multiple injections of allergen	86	1,229	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fasenra	Benralizumab	24	1,232	$136,358
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	114	5,430	$114,005
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	63	2,880	$55,387
Breo Ellipta	Fluticasone/Vilanterol	100	4,380	$55,028
Xolair	Omalizumab	12	504	$51,232

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7631	Cromolyn sodium, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams	N	N/R	11	$682
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	N	N/R	11	$599
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	11	$285

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$404	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Albert S. Hartel, MD?

Tedicare shows public-source Medicare data for Albert S. Hartel, MD (NPI 1841304805), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Albert S. Hartel, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Albert S. Hartel, MD?

Albert S. Hartel, MD is linked to ALLERGY ASTHMA IMMUNOLOGY OF ROCHESTER, PC (billing NPI 1043288293) in the available physician profile data.

Does Albert S. Hartel, MD have Open Payments data?

Albert S. Hartel, MD has 25 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.